nebulized Furosemide and spirometric indexes in Chronic Obstructive Pulmonary Disease exacerbation

The effect of nebulized Furosemide in Chronic Obstructive Pulmonary Disease exacerbation patients.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190109042305N1

Enrollment

Registered

2019-01-25

Start date

2018-09-22

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease exacerbation. Chronic obstructive pulmonary disease with (acute) exacerbation

Interventions

Intervention 1: Intervention group: The case group received 40 mg of furosemide (Chemidarou Industrial Company, Tehran, Iran, 20 mg/2 cc) in a 15-minute period. Intervention 2: Control group: The cont

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COPD exacerbation patients FEV1/FVC less than 70% No need for ventilator

Exclusion criteria

Exclusion criteria: FEV1 Increase greater than 200 cc or 12% after salbutamol administration in spirometry The history of infectious diseases such as tuberculosis, recent respiratory infections, bronchiectasis and acute or chronic diarrhea Probability of malignancy based on examination Rheumatic arthritis, degenerative joint disease, vasculitis

Design outcomes

Primary

Measure	Time frame
Forced expiratory volume in 1 second (FEV1). Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Forced vital capacity. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.	—

Secondary

Measure	Time frame
Peak Expiratory Flow Rate. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Severity of respiratory distress. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Accessory muscle score.;Adverse effect. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Patient evaluation.	—

Measure

Time frame

Peak Expiratory Flow Rate. Timepoint: Before prescribing medications, 30 minutes and one hour after administration. Method of measurement: spirometry.;Severity of respiratory distress. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Accessory muscle score.;Adverse effect. Timepoint: Before prescribing medications, as well as 30 minutes and one hour after administration. Method of measurement: Patient evaluation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMir Saeid Ramezani

Sari University of Medical Sciences

mramezani@mazums.ac.ir+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026